207 related articles for article (PubMed ID: 31319374)
1. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
Lea S; Metryka A; Li J; Higham A; Bridgewood C; Villetti G; Civelli M; Facchinetti F; Singh D
Cytokine; 2019 Nov; 123():154739. PubMed ID: 31319374
[TBL] [Abstract][Full Text] [Related]
2. Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.
Buenestado A; Grassin-Delyle S; Guitard F; Naline E; Faisy C; Israël-Biet D; Sage E; Bellamy JF; Tenor H; Devillier P
Br J Pharmacol; 2012 Mar; 165(6):1877-1890. PubMed ID: 21913898
[TBL] [Abstract][Full Text] [Related]
3. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
4. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
Singh D; Lea S; Mathioudakis AG
Drugs; 2021 Nov; 81(16):1821-1830. PubMed ID: 34731461
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
Reddy AT; Lakshmi SP; Banno A; Reddy RC
Int J Chron Obstruct Pulmon Dis; 2020; 15():125-134. PubMed ID: 32021151
[TBL] [Abstract][Full Text] [Related]
6. The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
Gianello V; Salvi V; Parola C; Moretto N; Facchinetti F; Civelli M; Villetti G; Bosisio D; Sozzani S
Biochem Pharmacol; 2019 May; 163():371-380. PubMed ID: 30851246
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
Milara J; Peiró T; Serrano A; Guijarro R; Zaragozá C; Tenor H; Cortijo J
Pulm Pharmacol Ther; 2014 Aug; 28(2):138-48. PubMed ID: 24525294
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.
Buenestado A; Chaumais MC; Grassin-Delyle S; Risse PA; Naline E; Longchampt E; Tenor H; Devillier P
PLoS One; 2013; 8(9):e74640. PubMed ID: 24066150
[TBL] [Abstract][Full Text] [Related]
9. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Tannheimer SL; Wright CD; Salmon M
Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
[TBL] [Abstract][Full Text] [Related]
10. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
[TBL] [Abstract][Full Text] [Related]
11. Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.
Dunne AE; Kawamatawong T; Fenwick PS; Davies CM; Tullett H; Barnes PJ; Donnelly LE
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):445-453. PubMed ID: 30395484
[TBL] [Abstract][Full Text] [Related]
12. Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Totani L; Amore C; Di Santo A; Dell'Elba G; Piccoli A; Martelli N; Tenor H; Beume R; Evangelista V
J Thromb Haemost; 2016 Jan; 14(1):191-204. PubMed ID: 26484898
[TBL] [Abstract][Full Text] [Related]
13. Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.
Singh D; Beeh KM; Colgan B; Kornmann O; Leaker B; Watz H; Lucci G; Geraci S; Emirova A; Govoni M; Nandeuil MA
Respir Res; 2019 Aug; 20(1):180. PubMed ID: 31399091
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
[TBL] [Abstract][Full Text] [Related]
15. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Mokry J; Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D
J Physiol Pharmacol; 2017 Oct; 68(5):721-730. PubMed ID: 29375047
[TBL] [Abstract][Full Text] [Related]
16. Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.
Feng H; Wang C; He W; Wu X; Li S; Zeng Z; Wei M; He B
Metab Brain Dis; 2019 Apr; 34(2):583-591. PubMed ID: 30610438
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of roflumilast.
Lahu G; Nassr N; Hünnemeyer A
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells.
Victoni T; Gleonnec F; Lanzetti M; Tenor H; Valença S; Porto LC; Lagente V; Boichot E
PLoS One; 2014; 9(1):e85243. PubMed ID: 24416369
[TBL] [Abstract][Full Text] [Related]
19. The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.
Rieder F; Siegmund B; Bundschuh DS; Lehr HA; Endres S; Eigler A
PLoS One; 2013; 8(2):e56867. PubMed ID: 23468885
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]